Alliance Medical Radiopharmacy (AMR) has achieved a significant regulatory milestone following MHRA approval for the inclusion of its AMR Guildford and AMR Dinnington manufacturing facilities within the ABX Marketing Authorisation dossier for Radelumin® 2000 MBq/mL solution for injection ([18F]PSMA-1007). Radelumin® will now be supplied commercially from both sites in the North and South of England, supporting healthcare providers across the UK.

AMR has supplied [18F]PSMA-1007 to customers for several years under a Manufacturing Specials (MS) license. The move to fully Product Licensed (PL) commercial supply as Radelumin® marks the product's transition from MS supply to licensed commercial availability, providing clinicians with assurance of a fully authorised product whilst maintaining the service and reliability they already expect from AMR.

The milestone reflects Alliance Medical's continued investment in radiopharmaceutical manufacturing, quality systems and regulatory excellence, helping to support dependable nationwide supply for prostate cancer imaging services and further reinforcing Alliance Medical Group's position as the UK's leading provider of molecular imaging and radiopharmacy services.
Axel Schmidt, General Manager, Alliance Medical Radiopharmacy, said:

"This is an important achievement for our radiopharmacy team and for the healthcare providers we support. Customers who are already familiar with [18F]PSMA-1007 can continue to rely on the same expertise, service and supply infrastructure, further strengthened by fully licensed Radelumin® commercial supply. We're proud to have reached this milestone and to continue supporting healthcare providers across the UK with confidence."

For more information about our radiotracer production and supply in the UK, please contact Leisl Anderson, Market Development Manager for Radiopharmacy: landerson@alliance.co.uk

‍